oral semaglutide phase 3 Type 2 diabetes just got a new front-runner in the race to replace injections with a pill. A head-to-head trial called ACHIEVE-3, presented at the ADA 86th Scientific Sessions and oral semaglutide phase 3 🥼🧪Slide

[2] These studies should be read as laboratory and preclinical model evidence, not as proof of clinical benefit

(A reminder: GLP-1s were developed originally to help regulate blood sugar for people with diabetes, and then started to get prescribed off-label because of their weight loss effects.) It's not just weight loss, though

Not realistically

The change of plasma metabolic profile and gut microbiome dysbiosis in patients with rheumatoid arthritis

The Baton Rouge General Weight Loss Center aims to help patients explore medical weight loss options, including popular GLP-1 drugs, while addressing the broader factors that contribute to health outcomes